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Abstract 
The antimicrobial activity of eugenol and the non-polar extract from cloves (Syzygium aromaticum), was tested against the Staphylococcus 
aureus strain resistant to cefotaxime, Escherichia coli and Candida albicans using the disc diffusion antibiotic sensitivity technique. Soxhlet 
extraction was performed to separate the essential oil and GCMS method was used to identify the eugenol which is the main component of the 
clove essential oil. The measured growth inhibition zones showed significant activity against the 3 microbes. To conclude, eugenol is the 
major active ingredient of the clove essential oil extract. 
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INTRODUCTION 
Staphylococcus aureus (S. aureus) is Gram-positive bacterium 
from the Staphylococcaceae family and a normal flora in the 
respiratory tract, nose and on the skin.  It can cause a variety of 
diseases in man according to the intrinsic virulence and the status 
of host’s immune system. Although it is not always pathogenic, it 
can cause skin infections, respiratory infections and food 
poisoning when the immune system is depressed [1].   
The major problem with S. aureus and other types of bacteria is 
that they have the ability to develop resistance against a wide 
range of antibiotics, leading to worldwide MRSA (Methicillin 
Resistance Staphylococcus aureus) problem.  
MRSA is prevalent in European countries ranges from less than 
1% in countries like Norway, to more than 40% in the UK [2] 
hence, the growing concerns about how to control that threat. 
Escherichia coli (E. coli) is a Gram-negative and aerobic 
commensal bacterium from the Enterobacteriaceae family that is 
showing a worldwide emergence of multidrug resistance. It 
mainly causes enteric and diarrheal diseases, urinary tract 
infections and sepsis/meningitis [3].  
Candida albicans (C. albicans) is a saprophyte and commensal 
yeast from the Saccharomycetaceae family and a member of the 
human gut flora. It is also an important human fungal pathogen 
that causes invasive and difficult to treat fungal infections [4], 
thus it involves an increase of medical and economic issues 
related to the high mortality rates, the increased costs of care and 
of duration of hospitalization [5].  
To deal with the antibiotic resistance problem against currently 
used antibiotics, scientists should look for new alternatives such 
as plant origin substances that have proved their efficacy against 
microbial infections. Here we investigated the efficacy of clove 
oil extracts compared with pure eugenol against the three 
mentioned microbes. 
Cloves, also known as Eugenia aromatica, are dried buds 
harvested when the calyces change from green to yellow pink. 
They come from the evergreen tree Syzygium aromaticum (S. 
aromaticum) from the Myrtaceae family, which flowers twice a 
year, and grows in tropical and subtropical conditions [6]. Cloves 
have been used in Ayurveda, Chinese medicine and Western 
herbalism for many medicinal purposes since ancient times [7]. 
Nowadays, the clove oil from S. aromaticum and eugenol are well 
known to present strong antibacterial and antifungal activities [8, 
9] that have been tested in several animal models [10]. In order to
improve our knowledge about the microorganisms’ behaviour
against S. aromaticum extracts, it is necessary to carry out more
studies like this one.
MATERIALS AND METHODS 
Extraction and diffusion disk preparation: 92.2 grams of dry 
and ground clove was added to 200ml of dichloromethane (Fisher 
Scientific) and was subjected to 2 hours of sonication at room 
temperature. After sonication, the clove powder was filtered using 
Whatman® Qualitative cellulose filter paper and the volume of 
filtrate was reduced using a rotary evaporator.  The concentrated 
filtrate was further extracted using a soxhlet extractor with 500ml 
dichloromethane boiling at 55°C for 18 hours. The resulting 
extract was concentrated using a rotary evaporator, yielding 15.4 
grams of solvent free essential oil. The non-polar oil extract was 
further analysed using GC-MS. Analysis was performed using a 
Thermo scientific column (TG-SQ3 P/N26070-1300, 15m length, 
I.D. 0.25mm, film thickness 0.25 μm), oven temperature 40 °C for
1 minute, 40 to 200 °C at a rate of 6 °C/min and from 200 to 280
°C at a rate of 30 °C/min. The injector temperature was 250 °C,
the used carrier gas was helium at a linear velocity of 1 ml/min.
The ion source temperature was 250 °C and the ionisation energy
was 70 eV. Mass ranges between 20 and 500 amu (atomic mass
unit). Oil extract and pure eugenol were diluted by DCM to 0.1%
(v/v) for the extracted oil and 0.05% (v/v) for the eugenol
standard before injection.
The standard and the extract were stored at 4 °C before being used
to prepare the diffusion disks. Paper disks were soaked in the
extracted essential oil, eugenol or corn oil blank for one hour and
dried overnight in a plate drier before being used in the growth
inhibition test.
Bacterial and yeast culture 
S. aureus, E. coli and C. albicans were used as models based on
their medical importance. Stock cultures of S. aureus, E. coli
(prepared from Thermo Scientific™ Culti-Loops™ ) were
inoculated on nutrient agar (Oxoid™ Nutrient Agar)  whereas the
C. albicans was inoculated on Oxoid™  Sabouraud dextrose agar
(SDA), cultured plates were incubated for 24 hours at 37°C. The 2
types of bacteria and the yeast were then grown in nutrient broth
at 37°C and 28°C respectively for 24 hours.
Determination of growth inhibition zone: 
Antibacterial and antifungal activities of eugenol and the clove 
extract against the 3 organisms were examined using the agar disk 
diffusion method; the previously prepared disks where placed on 
freshly inoculated plates from the broth cultures. Replicates of 
each culture were prepared and Cefotaxime antibiotic discs 
(Oxoid™)  were used as test control. Discs loaded with corn oil 
were used as blank control.  After 48 hours of incubation, the 
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Table 1: The mean dimeters ± standard errors of growth inhibition zones of the 4 different treatments; Cefotaxime, Eugenol, Non polar extract, 
Corn oil 
Disc content  
Tested culture  
Cefotaxime 
30 µg/ disk 
Eugenol 
57µg/ disk 
Non polar extract 
35 µg/ disk 
Corn oil 
57 µg/ disk 
C. albicans 0.0 mm 12.1 ± 2.2 mm 9.7 ± 1.9 mm 0.0 mm 
E. coli 10.2±1.5 mm 4.2 ± 1.0 mm 3.4 ± 0.7 mm 0.0 mm 
S. aureus 0.0±0 mm 3.8 ± 0.7 mm 3.0 ± 0.6 mm 0.0 mm 
 
 
Figure 1: GC-MS non-polar extract, main peak of eugenol with retention time = 12.81min 
 
 
diameters of the growth inhibition zones around the disks were 
measured and the resistance to the antibiotic, standard and extracts 
was determined. The one-way analysis of variance (ANOVA) was 
used to determine whether the differences between the different 
treatments were statistically significant using IBM SPSS 
Statistics. 
 
RESULTS 
Eugenol was detected in the oil extract chromatogram as the 
major peak at retention time of 12.81min. It was identified using 
eugenol standard which turned up at retention time of 12.67min 
when the same GC method was used (Figure1 and 2).  
Compared with the standard and the wide range antibiotic, the 
antibacterial and antifungal activities of the clove non-polar 
extract were significant. The results showed that C. albicans was 
more sensitive to the non-polar extract and the eugenol standard 
than the E. coli or the S. aureus when the diameters of the growth 
inhibition zones around the relevant discs were measured. The 
activity against both the Gram-negative and the Gram-positive 
bacteria showed a similar pattern of growth inhibition (Table 1). 
With approximately half the concentration of the eugenol 
standard, the non-polar clove extract has similarly and 
significantly inhibited the growth rate of E. coli (Table 1). The 
known antibiotic Cefotaxime showed a significantly greater 
inhibition zone of the E. coli growth  than that of the clove extract 
at the same concentration: ANOVA F(3,46) = 229.00, P < 0.001 
(Figure 2A). Both eugenol standard and the clove non-polar 
extract showed highly significant inhibition in the growth of the 
gram positive bacteria S. aureus which is highly resistant to the 
Cefotaxime antibiotic at approximately the same concentration: 
ANOVA F(3,46) = 179.22, P < 0.001 (Figure 2B). The antifungal 
activity of the clove non-polar extract was highly significant 
against the yeast C. albicans: ANOVA F(2,37) = 143.60, P < 
0.001 (Figure 2C).  
 
DISCUSSION 
Although, the concentration of eugenol standard was 
approximately two times more than that of the clove extract, the 
growth inhibition zones around the eugenol discs were slightly 
larger than those of the extract which may reflect the contribution 
of other components of that extract in the yeast growth inhibition. 
In this short study, we examined the efficacy of clove (Syzygium 
aromaticum) essential oil against resistant microbes. Non-polar 
extracts of clove exhibited antimicrobial activity against three 
pathogenic organisms in vitro. The yeast (C. albicans) was the 
most sensitive to the extract and the standard eugenol, which 
indicates the need for further studies to profile the active 
components of the oil extract and to understand the exact 
mechanism of action in prokaryotic and eukaryotic 
microorganisms.     
However, the high content of eugenol in the non-polar extract 
appears to be responsible for its strong antimicrobial activity. The 
variation in the rate of inhibition could be due to the quality of the 
used discs (ability of paper to absorb and release the oil). It may 
also result from the synergistic effect of other minor components 
in the extract such as carvacrol and thymol [11].  
The modes of action of eugenol’s antimicrobial activity were 
discussed in previous studies; the hydrophobicity of the oil 
enables it to partition the lipids and disrupt the outer membrane of 
Gram- positive and Gram- negative bacteria [12]. Eugenol also 
found to enhance protein leakage of cell membranes in both types 
of bacteria [13]. 
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Figure 2: Mean inhibition zone diameter + SE, A) E. coli, B) S. 
aureus C) C. albicans 
CONCLUSION 
Clove contains bioactive compounds which can be potentially 
used for medicinal purposes. Eugenol is the major component of 
the clove essential oil and it is the main responsible compound for 
the antimicrobial activity of that extract. This study showed no 
sufficient evidence to support the synergistic effect of other 
compounds in the clove oil as both the extract and the eugenol 
standard showed similar pattern of antimicrobial activity.  Further 
studies are required, before the incorporation of eugenol into a 
drug formulation. The exact mechanism of action must be fully 
understood and a pharmacological evaluation is needed to 
determine the effective dosage and minimise any potential side 
effects [14].  
ACKNOWLEDGEMENTS 
This work was sponsored by the Faculty of Pharmacy, University 
Paris-Sud.  
The experimental work was carried out at Joseph Banks 
Laboratories, University of Lincoln. 
Our great thanks to Dr Nick Riess for his help with the GC-MS 
analysis. 
REFERENCES 
[1] Geerlings, S.E. and Hoepelman, A.I., Pathog Dis. 1999, 26, 259 –
265. (1999). 
[2] Otter, J.A. and French, G.L., Lancet Infect Dis. 2010, 10, 227– 239. 
[3] Huttner, A., Hatz, C., van den Dobbelsteen, G., Abbanat, D.,
Hornacek, A., Frölich, R., Dreyer, A.M., Martin, P., Davies, T., Fae,
K., van den Nieuwenhof, I., Lancet Infect Dis. 2017, 17, 528 – 537. 
[4] Mayer, F. L., Wilson, D., Hube, B., Virulence. 2013, 4, 119 –128. 
[5] Slavin, M., Fastenau, J., Sukarom, I., Mavros, P., Crowley, S. and
Gerth, W.C., Int. J. Infect. Dis. 2004, 8, 111–120.
[6] Skelly, C.J., Dictionary of Herbs, Spices, Seasonings, and Natural
Flavorings, Routledge 1994. 
[7] Saeed, S. and Tariq, P., Pakistan J Botany. 2008, 40, 2157– 2160. 
[8] Fu, Y., Zu, Y., Chen, L., Shi, X., Wang, Z., Sun, S. and Efferth, T.,
J. Ethnopharmacol. 2007, 21, 989 – 994. 
[9] Devi, K.P., Nisha, S.A., Sakthivel, R. and Pandian, S.K., J.
Ethnopharmacol. 2010, 130, 107 – 115. 
[10] Chen, F., Shi, Z., Neoh, K. g., Kang, E. t., Biotechnol. Bioeng. 2009,
104, 30 – 39. 
[11] Pandey, A. and Singh, P., AJPSKY. 2011, 1, 69 – 80. 
[12]  Walsh, S.E., Maillard, J.Y., Russell, A.D., Catrenich, C.E.,
Charbonneau, D.L., Bartolo, R.G., J. Appl. Microbiol. 2003, 94, 240
– 247.
[13] Oyedemi, S.O., Okoh, A.I., Mabinya, L.V., Pirochenva, G. and
Afolayan, A.J., Afr. J. Biotechnol. 2009, 8, 1280 – 1286. 
[14] Hemaiswarya, S., Doble, M., Phytomedicine. 2009,16, 997 – 1005. 
Coralie Pavesi et al /J. Pharm. Sci. & Res. Vol. 10(2), 2018, 337-339
339
